Nicotine vaccines to treat tobacco dependence

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 1, 2013, Pages 13-25

  Goniewicz, MacIej L ^a   Delijewski, Marcin ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Cigarette smoking; Dopamine; Drugs of abuse; Nicotine; Nicotine addiction; Relapse prevention; Smoking cessation; Vaccines

Indexed keywords

AMFEBUTAMONE; ANXIOLYTIC AGENT; BROMOCRIPTINE; CANNABINOID 1 RECEPTOR ANTAGONIST; CLONIDINE; COTININE; CYT 002; CYTOCHROME P450 INHIBITOR; DIAMORPHINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHAMPHETAMINE; MONOAMINE OXIDASE INHIBITOR; MORPHINE; N,N(DISULFANEDIYLDIETHANE 2,1 DIYL)BIS[4 (2 PYRIDIN 3 YLPYRROLIDIN 1 YL)BUTANAMIDE]; NICOTINE VACCINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; NICQB; NORTRIPTYLINE; OPIATE ANTAGONIST; PLACEBO; SEL 068; TAN NIC; UNCLASSIFIED DRUG; VARENICLINE;

ACTIVE IMMUNIZATION; ANTIBODY AFFINITY; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTING CELL; BINDING SITE; BLOOD BRAIN BARRIER; CAUSE OF DEATH; DISTRIBUTION VOLUME; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EQUILIBRIUM CONSTANT; FLU LIKE SYNDROME; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INJECTION SITE CONTUSION; INJECTION SITE DISCOLORATION; INJECTION SITE DISCOMFORT; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALAISE; MYALGIA; NEUROPHARMACOLOGY; NICOTINE REPLACEMENT THERAPY; NONHUMAN; PARESTHESIA; PASSIVE IMMUNIZATION; REINFORCEMENT; RELAPSE; REVIEW; SIDE EFFECT; SMOKING; SMOKING CESSATION; STEADY STATE; SUBSTANCE ABUSE; TASTE DISORDER; TOBACCO DEPENDENCE; WEIGHT; WITHDRAWAL SYNDROME; XEROSTOMIA;

CIGARETTE SMOKING; DOPAMINE; DRUGS OF ABUSE; NICOTINE; NICOTINE ADDICTION; RELAPSE PREVENTION; SMOKING CESSATION; VACCINES;

HUMANS; NICOTINE; TOBACCO USE DISORDER; TREATMENT OUTCOME; VACCINATION; VACCINES;

EID: 84874736726     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.22060     Document Type: Review

References (73)

1. UN Office on Drugs and Crime. World drug report 2011. [http://www.humansecuritygateway.com/show-Record.php?RecordId=35492 (accessed on March 15, 2012)]
2. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012; 379:55-70; PMID:22225671; http://dx.doi.org/10.1016/S0140-6736(11)61138-0.
3. Kessler R, Üstün T. The WHO World Mental Health Surveys: global perspectives on the epidemiology of mental disorders. Cambridge: Cambridge University Press, 2008.
4. Degenhardt L, Chiu WT, Sampson N, Kessler RC, Anthony JC, Angermeyer M, et al. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: findings from the WHO World Mental Health Surveys. PLoS Med 2008; 5:e141; PMID:18597549; http://dx.doi.org/10.1371/journal.pmed.0050141.
5. Daniel JZ, Hickman M, Macleod J, Wiles N, Lingford-Hughes A, Farrell M, et al. Is socioeconomic status in early life associated with drug use? A systematic review of the evidence. Drug Alcohol Rev 2009; 28:142-53; PMID:19320699; http://dx.doi.org/10.1111/j.1465-3362.2008.00042.x.
6. Glantz MD, Anthony JC, Berglund PA, Degenhardt L, Dierker L, Kalaydjian A, et al. Mental disorders as risk factors for later substance dependence: estimates of optimal prevention and treatment benefits. Psychol Med 2009; 39:1365-77; PMID:19046473; http://dx.doi.org/10.1017/S0033291708004510.
7. WHO. The ICD-10 classification of mental and behavioural disorders -diagnostic criteria for research. Geneva: World Health Organization, 1993.
8. APA. Diagnostic and statistical manual of mental disorders: DSM-IV-TR, 4th edn. Washington, DC: American Psychiatric Association, 2000.
9. Diana M. The dopamine hypothesis of drug addiction and its potential therapeutic value. Front Psychiatry 2011; 2:64; PMID:22144966; http://dx.doi.org/10.3389/fpsyt.2011.00064.
10. Stotts AL, Dodrill CL, Kosten TR. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother 2009; 10:1727-40; PMID:19538000; http://dx.doi.org/10.1517/14656560903037168.
11. Kahan M, Srivastava A, Ordean A, Cirone S. Buprenorphine: new treatment of opioid addiction in primary care. Can Fam Physician 2011; 57:281-9; PMID:21402963.
12. Vadivelu N, Hines RL. Buprenorphine: a unique opioid with broad clinical applications. J Opioid Manag 2007; 3:49-58; PMID:17367094.
13. Kreek MJ, Borg L, Ducat E, Ray B. Pharmacotherapy in the treatment of addiction: methadone. J Addict Dis 2010; 29:200-16; PMID:20407977; http://dx.doi.org/10.1080/10550881003684798.
14. Shen XY, Orson FM, Kosten TR. Vaccines against drug abuse. Clin Pharmacol Ther 2012; 91:60-70; PMID:22130115; http://dx.doi.org/10.1038/clpt.2011.281.
15. Moreno AY, Janda KD. Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence. Pharmacol Biochem Behav 2009; 92:199-205; PMID:19350728; http://dx.doi.org/10.1016/j.pbb.2009.01.015.
16. Carroll FI, Blough BE, Pidaparthi RR, Abraham P, Gong PK, Deng L, et al. Synthesis of mercapto-(+)-methamphetamine haptens and their use for obtaining improved epitope density on (+)-methamphetamine conjugate vaccines. J Med Chem 2011; 54:5221-8; PMID:21682289; http://dx.doi.org/10.1021/jm2004943.
17. Moreno AY, Mayorov AV, Janda KD. Impact of distinct chemical structures for the development of a methamphetamine vaccine. J Am Chem Soc 2011; 133:6587-95; PMID:21473576; http://dx.doi.org/10.1021/ja108807j.
18. Li QQ, Luo YX, Sun CY, Xue YX, Zhu WL, Shi HS, et al. A morphine/heroin vaccine with new hapten design attenuates behavioral effects in rats. J Neurochem 2011; 119:1271-81; PMID:21951213; http://dx.doi.org/10.1111/j.1471- 4159.2011.07502.x.
19. Haney M, Kosten TR. Therapeutic vaccines for substance dependence. Expert Rev Vaccines 2004; 3:11-8; PMID:14761239; http://dx.doi.org/10.1586/14760584.3. 1.11.
20. Esson L, Leeder SR. The millennium development goals and tobacco control: an opportunity for global partnership. Geneva: World Health Organization (WHO): 2004.
21. Tobacco Free Initiative (TFI). Why is tobacco a public health priority? World Health Organization (WHO): 2005 [http://www.who.int/tobacco/health- priority/en (accessed on March 15, 2012)]
22. Rose JE, Mukhin AG, Lokitz SJ, Turkington TG, Herskovic J, Behm FM, et al. Kinetics of brain nicotine accumulation in dependent and nondependent smokers assessed with PET and cigarettes containing 11C-nicotine. Proc Natl Acad Sci U S A 2010; 107:5190-5; PMID:20212132; http://dx.doi.org/10.1073/pnas. 0909184107.
23. Houtsmuller EJ, Henningfield JE, Stitzer ML. Subjective effects of the nicotine lozenge: assessment of abuse liability. Psychopharmacology (Berl) 2003; 167:20-7; PMID:12616334.
24. Benowitz NL. Nicotine addiction. N Engl J Med 2010; 362:2295-303; PMID:20554984; http://dx.doi.org/10.1056/NEJMra0809890.
25. Polosa R, Benowitz NL. Treatment of nicotine addiction: present therapeutic options and pipeline developments. Trends Pharmacol Sci 2011; 32:281-9; PMID:21256603; http://dx.doi.org/10.1016/j.tips.2010.12.008.
26. Frishman WH. Smoking cessation pharmacotherapy. Ther Adv Cardiovasc Dis 2009; 3:287-308; PMID:19491139; http://dx.doi.org/10.1177/1753944709335754.
27. Centers for Disease Control and Prevention. 2004 Surgeon General's Report -The health consequences of smoking. [http://www.cdc.gov/tobacco/data- statistics/sgr/2004/index.htm (accessed on March 15, 2012)]
28. Rose JE. Disrupting nicotine reinforcement: from cigarette to brain. Ann N Y Acad Sci 2008; 1141:233-56; PMID:18991961; http://dx.doi.org/10.1196/annals. 1441.019.
29. Kosten T, Owens SM. Immunotherapy for the treatment of drug abuse. Pharmacol Ther 2005; 108:76-85; PMID:16023218; http://dx.doi.org/10.1016/j. pharmthera. 2005.06.009.
30. Orson FM, Kinsey BM, Singh RAK, Wu Y, Gardner T, Kosten TR. Substance abuse vaccines. Ann N Y Acad Sci 2008; 1141:257-69; PMID:18991962; http://dx.doi.org/10.1196/annals.1441.027.
31. Escobar-Chávez JJ, Domínguez-Delgado CL, Rodríguez-Cruz IM. Targeting nicotine addiction: the possibility of a therapeutic vaccine. Drug Des Devel Ther 2011; 5:211-24; PMID:21607018; http://dx.doi.org/10.2147/DDDT.S10033.
32. Cerny EH, Cerny T. Vaccines against nicotine. Hum Vaccin 2009; 5:200-5; PMID:19276649; http://dx.doi.org/10.4161/hv.5.4.7310.
33. de Villiers SHL, Lindblom N, Kalayanov G, Gordon S, Baraznenok I, Malmerfelt A, et al. Nicotine hapten structure, antibody selectivity and effect relationships: results from a nicotine vaccine screening procedure. Vaccine 2010; 28:2161-8; PMID:20060511; http://dx.doi.org/10.1016/j.vaccine.2009.12.051.
34. Keyler DE, Dufek MB, Calvin AD, Bramwell TJ, LeSage MG, Raphael DE, et al. Reduced nicotine distribution from mother to fetal brain in rats vaccinated against nicotine: time course and influence of nicotine dosing regimen. Biochem Pharmacol 2005; 69:1385-95; PMID:15826609; http://dx.doi.org/10.1016/j.bcp.2005. 02.007.
35. LeSage MG, Keyler DE, Hieda Y, Collins G, Burroughs D, Le C, et al. Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine selfadministration in rats. Psychopharmacology (Berl) 2006; 184:409-16; PMID:15991003; http://dx.doi.org/10.1007/s00213-005-0027-2.
36. Sanderson SD, Cheruku SR, Padmanilayam MP, Vennerstrom JL, Thiele GM, Palmatier MI, et al. Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant. Int Immunopharmacol 2003; 3:137-46; PMID:12538044; http://dx.doi.org/10.1016/ S1567-5769(02)00260-6.
37. Keyler DE, Hieda Y, St Peter J, Pentel PR. Altered disposition of repeated nicotine doses in rats immunized against nicotine. Nicotine Tob Res 1999; 1:241-9; PMID:11072421; http://dx.doi.org/10.1080/14622299050011361.
38. Pravetoni M, Keyler DE, Pidaparthi RR, Carroll FI, Runyon SP, Murtaugh MP, et al. Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities. Biochem Pharmacol 2012; 83:543-50; PMID:22100986; http://dx.doi.org/10.1016/j.bcp.2011.11.004.
39. Selecta Biosciences: Recent news. Selecta Biosciences Initiates Phase 1 Clinical Study of SEL-068, a Firstin-Class Synthetic Nicotine Vaccine for Smoking Cessation and Relapse Prevention [http://www.selectabio.com/news/recent- news/Selecta-Biosciences-Initiates-Phase-1-Clinical-Study-of-SEL-068.cfm (accessed on January 14, 2012)]
40. Cornish KE, Harris AC, LeSage MG, Keyler DE, Burroughs D, Earley C, et al. Combined active and passive immunization against nicotine: minimizing monoclonal antibody requirements using a target antibody concentration strategy. Int Immunopharmacol 2011; 11:1809-15; PMID:21802529; http://dx.doi.org/10.1016/ j.intimp.2011.07.009.
41. Malin DH, Moon WD, Goyarzu P, Magallanes N, Blair MB, Alexander MR, et al. Passive immunization against nicotine attenuates somatic nicotine withdrawal syndrome in the rat. Nicotine Tob Res 2010; 12:438-44; PMID:20203107; http://dx.doi.org/10.1093/ntr/ntq021.
42. Raupach T, Hoogsteder PHJ, Onno van Schayck CP. Nicotine vaccines to assist with smoking cessation: current status of research. Drugs 2012; 72:e1-16; PMID:22356293; http://dx.doi.org/10.2165/11599900-000000000-00000.
43. Hasman A, Holm S. Nicotine conjugate vaccine: is there a right to a smoking future? J Med Ethics 2004; 30:344-5; PMID:15289514; http://dx.doi.org/ 10.1136/jme.2002.001602.
44. Kinsey BM, Jackson DC, Orson FM. Anti-drug vaccines to treat substance abuse. Immunol Cell Biol 2009; 87:309-14; PMID:19333250; http://dx.doi.org/10. 1038/icb.2009.17.
45. Keyler DE, Roiko SA, Earley CA, Murtaugh MP, Pentel PR. Enhanced immunogenicity of a bivalent nicotine vaccine. Int Immunopharmacol 2008; 8:1589-94; PMID:18656557; http://dx.doi.org/10.1016/j.intimp.2008.07.001.
46. Hieda Y, Keyler DE, Ennifar S, Fattom A, Pentel PR. Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol 2000; 22:809-19; PMID:10963853; http://dx.doi.org/10.1016/S0192-0561(00)00042-4.
47. Satoskar SD, Keyler DE, LeSage MG, Raphael DE, Ross CA, Pentel PR. Tissue-dependent effects of immunization with a nicotine conjugate vaccine on the distribution of nicotine in rats. Int Immunopharmacol 2003; 3:957-70; PMID:12810353; http://dx.doi.org/10.1016/S1567-5769(03)00094-8.
48. Pravetoni M, Keyler DE, Raleigh MD, Harris AC, Lesage MG, Mattson CK, et al. Vaccination against nicotine alters the distribution of nicotine delivered via cigarette smoke inhalation to rats. Biochem Pharmacol 2011; 81:1164-70; PMID:21333633; http://dx.doi.org/10.1016/j.bcp.2011.02.004.
49. Hatsukami DK, Jorenby DE, Gonzales D, Rigotti NA, Glover ED, Oncken CA, et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther 2011; 89:392-9; PMID:21270788; http://dx.doi.org/10.1038/clpt.2010.317.
50. Wagena EJ, de Vos A, Horwith G, van Schayck CP. The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: results of a randomized, placebo-controlled phase 1/2 trial. Nicotine Tob Res 2008; 10:213-8; PMID:18188762; http://dx.doi.org/10.1080/14622200701704921.
51. Cytos Biotechnology. CYT002 Nic Qb: a novel vaccine for nicotine addiction. Zurich: Cytos Biotechnology; 2012. [http://www.cytos.com/userfiles/ file/Cytos- Press-E-091015.pdf (accessed on January 15, 2012)]
52. Roiko SA, Harris AC, Keyler DE, Lesage MG, Zhang Y, Pentel PR. Combined active and passive immunization enhances the efficacy of immunotherapy against nicotine in rats. J Pharmacol Exp Ther 2008; 325:985-93; PMID:18305013; http://dx.doi.org/10.1124/jpet.107.135111.
53. Raupach T, van Schayck CP. Pharmacotherapy for smoking cessation: current advances and research topics. CNS Drugs 2011; 25:371-82; PMID:21476609; http://dx.doi.org/10.2165/11590620-000000000-00000.
54. Leader AE, Lerman C, Cappella JN. Nicotine vaccines: will smokers take a shot at quitting? Nicotine Tob Res 2010; 12:390-7; PMID:20185516; http://dx.doi.org/10.1093/ntr/ntq015.
55. Carrozzi L, Pistelli F, Viegi G. Pharmacotherapy for smoking cessation. Ther Adv Respir Dis 2008; 2:301-17; PMID:19124379; http://dx.doi.org/10.1177/ 1753465808096136.
56. Hall WD. Will nicotine genetics and a nicotine vaccine prevent cigarette smoking and smoking-related diseases? PLoS Med 2005; 2:e266, quiz e351; PMID:16173831; http://dx.doi.org/10.1371/journal.pmed.0020266.
57. Maurer P, Jennings GT, Willers J, Rohner F, Lindman Y, Roubicek K, et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol 2005; 35:2031-40; PMID:15971275; http://dx.doi.org/10.1002/eji.200526285.
58. Cornuz J, Zwahlen S, Jungi WF, Osterwalder J, Klingler K, van Melle G, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One 2008; 3:e2547; PMID:18575629; http://dx.doi.org/10.1371/journal. pone.0002547.
59. Successful Results from Second Clinical Trial of Anti-Smoking Vaccine, TA-NIC; 2004 [http://www.globenewswire. com/newsroom/news.html?d=60776 (accessed on January 15, 2012)]
60. Xenova Group plc: Anti-Smoking Vaccine TA-NIC Preliminary 12 Month Clinical Trial Results [press release]. Berkshire, UK: Xenowa Group; 2005 [http://www.globenewswire.com/newsroom/news. html?d=73733 (accessed on January 15, 2012)]
61. ClinicalTrials.gov [http://www.clinicaltrials.gov/ct2/show/NCT00633321? term=TA-NIC&rank=1 (accessed on January 14, 2012)]
62. Nabi Biopharmaceuticals: Clinical Trials. NicVAX® (Nicotine Conjugate Vaccine) [http://www.nabi.com/pipeline/clinicaltrials.php (accessed on November 11, 2012)]
63. Hatsukami DK, Rennard S, Jorenby D, Fiore M, Koopmeiners J, de Vos A, et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 2005; 78:456-67; PMID:16321612; http://dx.doi.org/10.1016/j.clpt.2005.08.007.
64. Nabi Biopharmaceuticals: News Release. Nabi Biopharmaceuticals Announces Results of Second NicVAX(R) Phase III Clinical Trial [http://phx. corporate-ir.net/phoenix.zhtml?c=100445&p=irolnewsArticle& ID=1626882&highlight (accessed on January 14, 2012)]
65. The Local. Sweden's News in English. Swedish antismoking vaccine to undergo tests [http://www.thelocal. se/11392/20080428/(accessed on March 15, 2012)]
66. Oliver JL, Pashmi G, Barnett P, Mettens P, Biemans R, Monteyne P, et al. Development of an anti-cotinine vaccine to potentiate nicotine-based smoking cessation strategies. Vaccine 2007; 25:7354-62; PMID:17870213; http://dx.doi.org/10.1016/j.vaccine.2007.08.019.
67. Bevins RA, Wilkinson JL, Sanderson SD. Vaccines to combat smoking. Expert Opin Biol Ther 2008; 8:379-83; PMID:18352843; http://dx.doi.org/10.1517/ 14712598.8.4.379.
68. Le Houezec J. Why a nicotine vaccine? Clin Pharmacol Ther 2005; 78:453-5; PMID:16321611; http://dx.doi.org/10.1016/j.clpt.2005.08.008.
69. Fahim RE, Kessler PD, Fuller SA, Kalnik MW. Nicotine vaccines. CNS Neurol Disord Drug Targets 2011; 10:905-15; PMID:22229310.
70. Keyler DE, Shoeman D, LeSage MG, Calvin AD, Pentel PR. Maternal vaccination against nicotine reduces nicotine distribution to fetal brain in rats. J Pharmacol Exp Ther 2003; 305:587-92; PMID:12606612; http://dx.doi.org/ 10.1124/jpet.102.046805.
71. Kuehn BM. Could a novel vaccine help smokers quit? JAMA 2005; 294:891-2; PMID:16118374; http://dx.doi.org/10.1001/jama.294.8.891.
72. LeSage MG, Keyler DE, Pentel PR. Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies. AAPS J 2006; 8:E65-75; PMID:16584135; http://dx.doi.org/10.1208/aapsj080108.
73. Gartner CE, Barendregt JJ, Wallace A, Hall WD. Would vaccination against nicotine be a cost-effective way to prevent smoking uptake in adolescents? Addiction 2012; 107:801-9; PMID:22084967; http://dx.doi.org/10.1111/j.1360-0443. 2011.03718.x.